G-Wave

HAGAR N.I.G. is a medical technology company that developed G-Wave, a non-invasive device for continuous glucose monitoring. The company was founded in 2017 by Guy Zur, Bentzi Gruber, Dr. Gerry Waintraub, and Taire Rubin. G-Wave's technology utilizes radio frequency (RF) waves to measure glucose levels directly in the blood, aiming to provide a painless and more accurate alternative to traditional, invasive methods. The concept was conceived by CTO Dr. Gerry Waintraub, an expert in RF technology, after an accidental discovery in his lab.

The company's primary product, G-Wave, is designed to be integrated into a wearable device, such as a smartwatch-sized bracelet, that communicates with a smartphone application. This allows users to track their glucose readings in real-time and share data with healthcare providers. The system is intended for both diabetic and prediabetic individuals, with the goal of improving diabetes management and enabling early detection and prevention of type 2 diabetes. Clinical tests have shown high accuracy, with the device monitoring glucose in the blood rather than interstitial fluid, which reduces delays and potential inaccuracies found in other continuous monitoring systems.

HAGAR has raised capital to fund its development and bring the product to market, completing a Series A funding round of $4.4 million in July 2021, which brought its total investment to $5.4 million. The company is focused on making the technology accessible and affordable for a global market.

Keywords: non-invasive glucose monitoring, continuous glucose monitor, G-Wave, HAGAR N.I.G., radio frequency medical device, diabetes management, medtech, wearable health tech, blood glucose monitoring, digital health, prediabetes detection, remote patient monitoring, smart bracelet, medical diagnostics, RF technology, Guy Zur, Gerry Waintraub, preventative medicine, healthcare technology, mobile health